Enerplus Corp produces and develops crude oil and natural gas assets in Canada and the United States. Majority of oil production is derived from the Williston and Waterfloods basins, with the Marcellus providing a significant portion of natural gas production. Enerplus acquires the right to use assets through royalties paid to government entities, land owners and mineral rights owners. Crude oil and natural gas are sold to customers in both countries where assets are held and can be sold either at the well or a fixed destination.
| Website: | www.enerplus.com |
| Email: | investorrelations@enerplus.com |
| Main Phone: | +1 403 298-2200 |
| Address: | 3000, 333 - 7th Avenue S.W. |
| Address 2: | The Dome Tower |
| State: | AB |
| City / Town: | Calgary |
| Country: | CAN |
| Postal Code: | T2P 2Z1 |
| Exchange: | NYE |
| CEO: | Ian C. Dundas |
| Employees: | 399 |
| NAICS: | Crude Petroleum Extraction(211120) |
How do we say that a drug costs “too much” when it can save or significantly extend a person’s life?
80 million annual exams in the US involve mydriasis (pupil dilation)
First transdermal product for this fast growing generic manufacturer (Image: Amneal Pharmaceuticals).
NeuBase will capture Ohr's Nasdaq listing as it develops therapies for genetic diseases caused by mutant proteins.
Investing in early-stage biotechnology companies requires great skill and patience (luck is always helpful as well).
Financing supports near-term initiation of Phase 2 trials in essential tremor and spinocerebellar ataxia (Image: Cadent Therapeutics).
Currently enrolling Phase 3 patients for cord blood cell therapy with potential to be universal curative stem cell graft (Image: Gamida Cell)
RTB101 shown to decrease incidence of infection with severe symptoms by 52.1% vs placebo (Image: resTORbio)
Clinical candidates for reversal agent for antiplatelet drug and for pulmonary arterial hypertension (Image: PhaseBio Pharmaceuticals)
Phase 3 data shows siponimod has beneficial effects on disability, relapses and MRI disease activities (Image: Novartis)
Enerplus Corp produces and develops crude oil and natural gas assets in Canada and the United States. Majority of oil production is derived from the Williston and Waterfloods basins, with the Marcellus providing a significant portion of natural gas production. Enerplus acquires the right to use assets through royalties paid to government entities, land owners and mineral rights owners. Crude oil and natural gas are sold to customers in both countries where assets are held and can be sold either at the well or a fixed destination.
| Website: | www.enerplus.com |
| Email: | investorrelations@enerplus.com |
| Main Phone: | +1 403 298-2200 |
| Address: | 3000, 333 - 7th Avenue S.W. |
| Address 2: | The Dome Tower |
| State: | AB |
| City / Town: | Calgary |
| Country: | CAN |
| Postal Code: | T2P 2Z1 |
| Exchange: | NYE |
| CEO: | Ian C. Dundas |
| Employees: | 399 |
| NAICS: | Crude Petroleum Extraction(211120) |
How do we say that a drug costs “too much” when it can save or significantly extend a person’s life?
80 million annual exams in the US involve mydriasis (pupil dilation)
First transdermal product for this fast growing generic manufacturer (Image: Amneal Pharmaceuticals).
NeuBase will capture Ohr's Nasdaq listing as it develops therapies for genetic diseases caused by mutant proteins.
Investing in early-stage biotechnology companies requires great skill and patience (luck is always helpful as well).
Financing supports near-term initiation of Phase 2 trials in essential tremor and spinocerebellar ataxia (Image: Cadent Therapeutics).
Currently enrolling Phase 3 patients for cord blood cell therapy with potential to be universal curative stem cell graft (Image: Gamida Cell)
RTB101 shown to decrease incidence of infection with severe symptoms by 52.1% vs placebo (Image: resTORbio)
Clinical candidates for reversal agent for antiplatelet drug and for pulmonary arterial hypertension (Image: PhaseBio Pharmaceuticals)
Phase 3 data shows siponimod has beneficial effects on disability, relapses and MRI disease activities (Image: Novartis)
| Last Price 5.55 | Change $ -0.18 | Change % -3.14 | Tick N/A |
| Bid N/A | Bid Size 0.00 | Ask N/A | Ask Size 0.00 |
| Open 5.65 | High 5.65 | Low 5.42 | Prev Close 5.73 |
| Last Trade | Volume 1.9 mi | 52 Wk Hi 9.74 | 52 Wk Low 5.43 |
| Market Cap 1.2 bi | Ex-Div Date | Div Rate 0.09 | Yield 1.6430 |
| Shares 221,743,701.00 | EPS (TTM) N/A | PE Ratio N/A | Exchange NYSE |
| Current | 1 Week Ago | 2 Weeks Ago | 3 Weeks Ago | |
|---|---|---|---|---|
| High Target Price Estimate | 15.8 | 15.8 | 15.8 | 18 |
| Low Target Price Estimate | 11.81 | 11.81 | 11.81 | 11.81 |
| Mean Target Price Estimate | 14.23 | 14.23 | 14.23 | 14.54 |
| Standard Deviation | 1.35 | 1.35 | 1.35 | 1.69 |
| Date of Most Recent Estimate | 05/18/18 | 05/18/18 | 05/18/18 | 06/18/18 |
| Current | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
|---|---|---|---|---|
| Strong Buy | 5 | 4 | 4 | 4 |
| Moderate Buy | 3 | 3 | 3 | 3 |
| Hold | 0 | 0 | 0 | 0 |
| Moderate Sell | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 |
| Mean Rec. | 1.38 | 1.43 | 1.43 | 1.43 |
© 2020 Equities News | Equities.com, Inc.
* All dates and time are being displayed in Eastern Standard Time (EST).
Gathering Data... Please wait